$BNTX

BioNTech SE

NasdaqMarket cap: —CIK 0001776985

Upcoming catalysts

0 surfaced

No catalysts surfaced for BNTX yet.

Drug pipeline

BNT3214

Advanced Solid Tumor Cancer

RO7198457 intravenous (IV)

Colorectal Cancer Stage II

BNT163

Genital Herpes Simplex Type 2

CLDN6 CAR-T

Testicular Germ Cell Tumor

BNT141

Solid Tumor

BNT321 0.5 mg/kg

Pancreatic Cancer

BNT314

Advanced Malignant Solid Tumor

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose

SARS-CoV-2 Virus

BNT323/DB-1303

Endometrial Cancer

Influenza and COVID-19 Combination A

Influenza

BNT323

Locally Advanced Breast Cancer

Investigational Influenza Vaccine

Influenza

BNT166a

Mpox (Monkeypox)

BNT324

Metastatic Castration-resistant Prostate Cancer

BNT113

Unresectable Head and Neck Squamous Cell Carcinoma

BNT411

Solid Tumor

Regular blood sample collection for ctDNA assessment

Colorectal Cancer Stage II

BNT164a1

Tuberculosis

Biological/Vaccine: BNT162b2 10mcg

SARS-CoV-2 Infection, COVID-19

BNT162b1

SARS-CoV-2

BNT162b2

SARS-CoV-2 Infection

Pumitamig

Recurrent Glioblastoma

BNT112

Prostate Cancer

BNT152

Solid Tumor

BNT162b2 Vaccine

COVID-19

BNT326

Non-small Cell Lung Cancer

BNT317 DL1

Advanced Solid Tumor

BNT329

Advanced Solid Cancers

BNT165b1

Malaria

BNT162b5 Bivalent (WT/OMI BA.2)

SARS-CoV-2 Infection

BNT142

Solid Tumor

BNT327 Dose Level 1 (DL1)

Extensive-stage Small-cell Lung Cancer

BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg

SARS-CoV-2 Infection

BNT162b2s01

COVID-19

BNT165e

Malaria

BNT3212

Advanced Solid Tumor

Lipo-MERIT

Melanoma

BNT162a1

Infections, Respiratory

BNT111

Melanoma Stage III

BNT162b3

Covid-19

BNT116

Non-Small Cell Lung Cancer

BNT331

Bacterial Vaginosis

bivalent BNT162b2 (original/Omi BA.4/BA.5)

Influenza, Human

BNT151

Solid Tumor

IVAC_W_bre1_uID

Breast Cancer (Triple Negative Breast Cancer (TNBC))

BNT351

HIV -1 Infection

BNT162b2 (2025/2026 formulation)

COVID-19

BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)

COVID-19

Recent & active trials

NCT	Drug	Phase	Status	Primary completion
NCT06940804	CLDN6 CAR-T	Phase 2	Withdrawn	2042-06-01
NCT07365995	BNT324	Phase 3	Recruiting	2031-02-01
NCT07079631	BNT314	Phase 2	Recruiting	2030-12-01
NCT07455734	BNT3214	Phase 2	Recruiting	2030-10-01
NCT07186842	BNT329	Phase 2	Recruiting	2030-05-01
NCT05142189	BNT116	Phase 1	Recruiting	2030-02-01
NCT07173751	Pumitamig	Phase 3	Recruiting	2029-12-01
NCT04534205	BNT113	Phase 3	Recruiting	2029-04-01
NCT06712316	Pumitamig	Phase 3	Recruiting	2029-02-01
NCT07111520	BNT326	Phase 2	Recruiting	2029-01-01
NCT06712355	Pumitamig	Phase 3	Recruiting	2028-12-01
NCT06841055	Pumitamig	Phase 2	Recruiting	2028-10-01
NCT06449222	BNT327 Dose Level 1 (DL1)	Phase 2	Active Not Recruiting	2028-08-01
NCT06750185	BNT317 DL1	Phase 1	Recruiting	2028-06-01
NCT06827236	BNT323	Phase 2	Recruiting	2028-05-01
NCT06340568	BNT323/DB-1303	Phase 3	Recruiting	2028-03-01
NCT07070232	BNT326	Phase 2	Recruiting	2028-02-01
NCT07297212	Pumitamig	Phase 2	Recruiting	2028-01-01
NCT07255404	Pumitamig	Phase 2	Recruiting	2027-12-01
NCT07147348	BNT3212	Phase 2	Recruiting	2027-11-01